Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US11274152B2 · kind B2 · utility
3Cited by
68References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2020 |
| Grant date | Mar 15, 2022 |
| Priority date | — |
| Expiry date | Sep 11, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.